Home | Welcome to Contract Pharma   
Last Updated Tuesday, May 21 2013
Print RSS Feed

Breaking News

Related Searches: Industry News

October 29, 2008
AMRI is expanding its multipurpose pilot plant facilities in Aurangabad, India for non-GMP manufacturing services to 1,000-liter scale capacity, which will allow the company to provide customized pilot scale materials. The new facility will serve as…  Read More »

October 29, 2008
Nicholas Moore, Ph.D. has been named director of development and pharmacology, discovery R&D, AMRI. Dr. Moore will be responsible for the company's internal R&D portfolio, including the progression of discovery phase programs and the guidance…  Read More »

October 29, 2008
Wendy Shusko has been named chief operating officer of WellSpring Pharmaceutical. In her new role, Ms. Shusko will maintain financial responsibilities as well as broaden her oversight to operations with an initial focus on the newly acquired consumer…  Read More »

October 28, 2008
Laureate Pharma has entered into a cGMP contract manufacturing agreement with Tolera Therapeutics, a biotechnology company that develops targeted therapies and safer solutions for immune modulation and related medical needs. Under the agreement, Laur…  Read More »

October 28, 2008
QSV Biologics Ltd. has formed an Australian subsidiary, QSV Biologics Australia Pty Ltd., and has appointed Dr. Neville McCarthy to its board of directors.      Dr. Graeme Macaloney, founder and chief executive officer, said,…  Read More »

October 28, 2008
Avid Bioservices, Inc. has signed a manufacturing supply agreement with Catalyst Biosciences to produce clinical-grade material for Catalyst's drug candidate, CB 813, a new version of factor VIIa for the treatment of acute bleeding in hemophilia pati…  Read More »

October 27, 2008
Bilcare Global Clinical Supplies has expanded its global distribution and warehousing capabilities for clinical trial supplies. The company has signed a service agreement with World Courier to use depots in Argentina, Brazil, Colombia, Chile, Mexico,…  Read More »

October 27, 2008
Cipher Pharmaceuticals has appointed John MacInnis as vice president, portfolio development and licensing. Mr. MacInnis will be responsible for identifying and evaluating pipeline products and technologies, and pursuing strategic alliances and partne…  Read More »

October 27, 2008
Celgene has terminated its licensing agreement with MethylGene for oncology histone deacetylase (HDAC) inhibitors, including MGCD0103. As a result, MethylGene will reacquire the rights to these programs. MethylGene also announced plans to implement a…  Read More »

October 24, 2008
GlaxoSmithKline Biologicals (a GSK unit) and AFFiRiS GmbH have entered a collaboration agreement granting GSK exclusive rights to AFFiRiS's Alzheimer's disease vaccine programs that target beta-amyloid. GSK is acquiring exclusive rights to develop an…  Read More »

October 24, 2008
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) has submitted a NDA to the FDA for carisbamate, an investigational compound for the adjunctive treatment of partial onset seizures in patients 16 years of age and ol…  Read More »

October 24, 2008
Elan 3Q Revenues: $270.1 million (+53%)  3Q Loss: $83.5 million  (loss of $87.4 million in 3Q07)  YTD Revenues: $730.4 million (+35%) YTD Loss: $240.5 million (loss of $321.5 million in YTD07) Comments: Biopharmaceuti…  Read More »

October 23, 2008
Patheon has opened a new Pharmaceutical Development Services (PDS) suite at its Whitby Development Center in Canada for the small-scale development and manufacturing of solid dosage forms for early clinical studies.     The 2,500-sq…  Read More »

October 23, 2008
Amgen 3Q Revenues: $3.9 billion (+7%) 3Q Earnings: $1.2 billion (earnings were $201 million in 3Q07) YTD Revenues: $11.3 billion (+3%) YTD Earnings: $3.2 billion (+39%) Comments: Sales of Aranesp were up 3% to $845 million. Sales of Ep…  Read More »

October 23, 2008
Lilly 3Q Revenues: $5.2 billion (+14%) 3Q Loss: $465.6 million (earnings were $926.3 million in 3Q07) YTD Revenues: $15.2 billion (+13%) YTD Earnings: $1.6 billion (-26%) Comments: Zyprexa sales were $1.2 billion in the quarter (+2%)…  Read More »

Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:

Follow Contract Pharma On